Caris Life Sciences Reports Third Quarter 2026 Financial Results and Increases
Caris Life Sciences Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
Revenue growth of 27% driven by strong performance in molecular profiling services, including approximately 61,500 clinical cases, consisting of over 358,000 total oncology tests
Raises 2026 revenue guidance to $1.04 to $1.05 billion, representing growth of 28% to 29%
— Caris Life Sciences, Inc. (Nasdaq: CAI), a leading TechBio company actively developing and commercializing solutions to transform healthcare, today reported financial results for the quarter ended September 30, 2026.
• Reported total revenue of $275.4 million, an increase of 27% over the corresponding prior year period.
• Completed approximately 61,500 clinical cases, an increase of approximately 21% over the corresponding prior year period.
• Reported net cash used in operating activities of $22.2 million, and free cash flow of $(39.7) million.
“This was another record quarter, with approximately 61,500 clinical cases, up 21% year over year,” said David Dean Halbert, Founder, Chairman and CEO of Caris Life Sciences. “Every case we run carries real molecular depth, whether Whole Exome, Whole Transcriptome, Whole Genome, or AI-driven digital pathology, and that depth is what allows us to move across the entire cancer journey. Caris Assure® is now available for therapeutic response monitoring, and Caris Confirm, our Whole Genome, tumor-informed assay for minimal residual disease, is targeted to launch before year-end. It all comes back to making precision medicine a reality for every patient through a comprehensive, data-driven approach.”
• Launched Caris Assure Therapy Response Monitoring, extending the Caris Assure blood-based platform from therapy selection to serial monitoring of treatment response.
• Launched enhanced Caris Assure for Therapy selection with therapy focused sequencing depth reaching 40,000x and increasing RNA reads to ~600M.
• Published validation of the Caris AI Insights™ pancreatic cancer signature, demonstrating that an AI-based molecular signature can predict first-line treatment benefits.
• Share repurchase program of up to $100.0 million, of which approximately $72.1 million remains available for repurchase under the existing Board authorization.
• Launched two national advertising campaigns featuring Kevin Costner and Jordan Spieth, spotlighting the importance of early-stage cancer detection and introducing Caris Detect™ to a consumer audience.
• Surpassed 1,200,000 total profiles and 845,000 total matched profiles through September 30, 2026. More than 849,000 Whole Transcriptome and 796,000 Whole Exome profiles through September 30, 2026.
Total revenue was $275.4 million for the three months ended September 30, 2026, compared to $216.8 million for the three months ended September 30, 2025, an increase of $58.5 million, or 27%.
The increase in total revenue was driven primarily by a 27% growth in molecular profiling services revenue, which was $262.7 million for the three months ended September 30, 2026, compared to $207.6 million for the three months ended September 30, 2025. The increase in molecular profiling services revenue was primarily driven by an increase in total clinical case volume and ASP improvements.
Gross profit, calculated as total revenue less cost of services, for the three months ended September 30, 2026 and 2025, was $182.3 million and $147.5 million, respectively, representing a gross margin of 66% and 68%, respectively.
Operating expenses were $163.0 million for the three months ended September 30, 2026, compared to $114.9 million for the three months ended September 30, 2025, an increase of $48.1 million, or 42%. The increase was primarily driven by headcount-related costs, increased research and development investment, and marketing expenditures.
Net income was $15.3 million for the three months ended September 30, 2026, as compared to a net income of $24.3 million for the three months ended September 30, 2025. Net income per share attributable to common shareholders, basic and diluted, was $0.05 and $0.05, respectively, for the three months ended September 30, 2026, as compared to a net income per share attributable to common shareholders, basic and diluted, of $0.09 and $0.08, respectively, for the three months ended September 30, 2025.
Net cash used in operating activities was $22.2 million for the three months ended September 30, 2026, as compared to net cash provided by operating activities of $62.4 million for the three months ended September 30, 2025, a 136% decrease. The decrease was driven by continued investment in commercial expansion and marketing expenditures, inventory build-up for new solution launches, and research and development efforts.
Caris Life Sciences now expects full year 2026 revenue to be in the range of $1.04 to $1.05 billion, representing growth of 28% to 29% compared to full year 2025 and reaffirms its guidance for clinical therapy selection volume growth of approximately 20% compared to full year 2025.
Accompanying materials will be posted on our investor relations website at https://investor.carislifesciences.com prior to the conference call. A replay of the conference call will be available on our investor relations website shortly after the conclusion of the call.
Caris Life Sciences® (Caris) is a leading TechBio company actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole
Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.
Caris was founded with a vision to realize the potential of precision medicine to improve the human condition. Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S. and other international markets.
We intend to use the investor page of our website, https://investor.carislifesciences.com , as a distribution channel of material information about the Company and for complying with our disclosure obligations under Regulation FD. The information we post on our investor webpage may be deemed material. Accordingly, investors should subscribe to our investor alerts, in addition to following our press releases, SEC filings, public conference calls and webcasts.
This press release contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding our business, solutions, plans, objectives, goals, industry trends, financial outlook and guidance. In some cases forward-looking statements can be identified by words such as “may,” “will,” “should,” “would,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “potential,” “contemplate,” “believe,” “estimate,” “predict,” or “continue” or similar expressions.
You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward- looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: continued development, performance and commercialization of Caris Detect and Caris Confirm; developments in the precision medicine industry; our future financial performance, results of operations or other operational results or metrics; development, analytical and clinical validation, timing and performance of future solutions by us and our competitors; commercial market acceptance for our solutions, including acceptance of preventive as well as diagnostic testing paradigms, and our ability to meet resulting demand; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions related to our solutions, including the effect of legislative, regulatory, or administrative actions on reimbursement; the impact on our future volumes of the continued execution of our strategy to re-align and expand our sales organization; risks related to data management, storage, and processing capabilities and our ability to integrate and deploy artificial intelligence and advanced data analytics technologies; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions; reliance on third-party suppliers; risks related to data security, patient privacy, and compliance with healthcare data protection regulations as well as potential cybersecurity threats to our data platforms; our compliance with laws and regulations; the outcome of government
investigations and litigation; risks related to our indebtedness; and our ability to hire and retain key personnel as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” and elsewhere in our Annual Report on Form 10-K filed on March 3, 2026, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law.
We use Adjusted EBITDA and free cash flow, financial measures not calculated in accordance with generally accepted accounting principles in the United States (“GAAP”), to supplement our condensed consolidated financial statements, which are presented in accordance with GAAP. We believe the non-GAAP financial measures we use, are useful in evaluating our performance and liquidity. Our non-GAAP financial measures have limitations as analytical tools, however, and you should not consider them in isolation or as substitutes for analysis of our results as reported under GAAP. Other companies, including other companies in our industry, may not use these measures or may calculate these measures differently than as presented herein, limiting their usefulness as comparative measures.
We define Adjusted EBITDA as net income (loss), adjusted to exclude interest income, interest expense, changes in fair value of financial instruments, other expense, net, the provision for (benefit from) income taxes, depreciation and amortization, and stock-based compensation expense. We use Adjusted EBITDA in conjunction with GAAP measures as part of our overall assessment of our performance, including the preparation of our annual operating budget and quarterly forecasts, to evaluate the effectiveness of our business strategies, and to communicate with our board of directors concerning our financial performance. We believe Adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results in the same manner as our management team and board of directors. Adjusted EBITDA provides a useful measure for period-to-period comparisons of our business, as it removes the effect of certain non-cash expenses and certain variable charges. We define free cash flow as net cash provided by (used in) operating activities less capitalized software and purchases of property and equipment. Our method of calculating free cash flow is unchanged from prior periods; the caption has been updated to identify capitalized software as a component of our investing capital expenditures. We believe free cash flow is a useful measure of liquidity that provides an additional basis for assessing our ability to generate cash.
A reconciliation of the non-GAAP financial measures used in this press release to the respective comparable GAAP financial measures, can be found below.
(amounts in thousands, except share data) Assets As of September As of December Current 30, 31, assets: 2026 2025 ────────────────────────────────────────────────────────────────────────────── Cash, cash equivalents, $ 665,321 $ 797,799 and restricted cash Short-term marketable 102,059 2,295 securities Accounts 133,322 112,140 receivable Supplies 138,372 63,625 Prepaid expenses and 28,194 21,941 other current assets Total current 1,067,268 997,800 assets Property and 102,295 63,170 equipment, net Goodwill 19,344 19,344 Other assets 66,716 45,349 Total assets $ 1,255,623 $ 1,125,663 Liabilities and Shareholders' Equity Current liabilities: Accounts $ 63,836 $ 39,206 payable Accrued expenses and 95,021 87,770 other current liabilities Current portion of 89 169 indebtedness Total current 158,946 127,145 liabilities Long-term indebtedness, 393,178 378,823 net Other long-term 64,018 42,388 liabilities Total 616,142 548,356 liabilities Commitments and contingencies Shareholders' equity: Preferred stock, $0.001 par value per share; 100,000,000 shares authorized as of September 30, 2026 and December 31, — — 2025; no shares issued and outstanding as of September 30, 2026 and December 31, 2025 Common stock, $0.001 par value per share; 2,800,000,000 shares authorized as of September 30, 2026 and December 31, 2025; 286,717,657 and 284,137,810 shares issued as of September 30, 2026 and December 31, 2025, respectively; 286,717,657 and 287 283 282,526,097 shares outstanding as of September 30, 2026 and December 31, 2025, respectively; shares issued and outstanding include 3,288 and 23,446 unvested shares subject to repurchase as of September 30, 2026 and December 31, 2025, respectively Treasury stock at cost, 0 and 1,611,713 shares of common stock as of — -16,896 September 30, 2026 and December 31, 2025, respectively Additional paid-in 3,173,932 3,141,720 capital Accumulated -2,534,633 -2,548,736 deficit Accumulated other comprehensive -105 936 income (loss) Total shareholders' 639,481 577,307 equity Total liabilities and $ 1,255,623 $ 1,125,663 shareholders' equity
(amounts in thousands) Nine Months Ended Cash flows from September 30, operating activities 2026 2025 ────────────────────────────────────────────────────────────────────────────── Net income (loss) $ 14,103 $ -150,045 Adjustments to reconcile net income (loss) to net cash provided by operating activities: Depreciation and 18,209 18,324 amortization Stock-based 56,589 56,639 compensation expense Non-cash operating 4,321 4,323 lease expense Amortization of debt 3,234 12,163 discounts Changes in fair value of financial — 52,284 instruments Loss on debt 25,232 17,930 extinguishment Other 3,074 788 Changes in operating assets and liabilities: Accounts receivable -21,182 61,232 Supplies -78,467 -11,144 Prepaid expenses and other current -5,711 -4,805 assets Other assets -409 -326 Accounts payable 18,042 -1,196 Accrued expenses and 2,072 -17,792 other liabilities Net cash provided by operating 39,107 38,375 activities Cash flows from investing activities Sale of marketable 1,874 — securities Purchases of -101,991 — marketable securities Capitalized software and purchases of -49,887 -11,170 property and equipment Net cash used in -150,004 -11,170 investing activities Cash flows from financing activities Payments made on finance lease -125 -67 obligations Proceeds from exercise 26,054 3,775 of stock options Payment of taxes withheld from net settlement of -5,426 -18,218 exercised options and vested RSUs Payment of deferred — -7,710 offering costs Repurchase of common -31,371 -22 stock Repayment of the 2023 -406,307 — term loan Proceeds from the 2026 term loan, net of 393,500 — issuance costs Payment of third-party debt issuance -1,107 — costs Proceeds from share purchases under 2,937 — employee stock purchase plan Issuance of Series E Preferred Stock, — 87,637 net of issuance costs Issuance of Series F Preferred Stock, — 33,601 net of issuance costs Issuance of the 2025 Convertible Notes, — 27,865 net of issuance costs Issuance of the 2025 — 10,270 Warrants Payments of the 2023 term loan amendment — -4,000 fee Proceeds from initial public offering, net of underwriting — 528,459 discounts and commissions Net cash provided by (used in) financing -21,845 661,590 activities Effect of exchange rate changes on cash, -149 159 cash equivalents, and restricted cash Net increase (decrease) in cash, cash -132,891 688,954 equivalents, and restricted cash Cash, cash equivalents, and restricted 800,042 68,028 cash at beginning of period Cash, cash equivalents, and $ 667,151 $ 756,982 restricted cash at end of period Reconciliation of cash, cash equivalents, and restricted cash Cash, cash equivalents, and $ 665,321 $ 754,739 restricted cash Restricted cash included in other 1,830 2,243 long-term assets Total cash, cash equivalents, and $ 667,151 $ 756,982 restricted cash
RECONCILIATION OF NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES TO FREE CASH FLOW (UNAUDITED)
Full text with the tables
Exhibit 99.1
Caris Life Sciences Reports Third Quarter 2026 Financial Results and Increases
2026 Revenue Guidance
Revenue growth of 27% driven by strong performance in molecular profiling
services, including approximately 61,500 clinical cases, consisting of over
358,000 total oncology tests
Raises 2026 revenue guidance to $1.04 to $1.05 billion, representing growth of
28% to 29%
IRVING, Texas, November 04, 2026
— Caris Life Sciences, Inc. (Nasdaq: CAI), a leading TechBio company actively
developing and commercializing solutions to transform healthcare, today reported
financial results for the quarter ended September 30, 2026.
Third Quarter 2026 Financial Highlights
• Reported total revenue of $275.4 million, an increase of 27% over the
corresponding prior year period.
• Completed approximately 61,500 clinical cases, an increase of approximately
21% over the corresponding prior year period.
• Reported gross margin of 66%.
• Reported net income of $15.3 million.
• Reported positive Adjusted EBITDA of $44.4 million.
• Reported net cash used in operating activities of $22.2 million, and free cash
flow of $(39.7) million.
“This was another record quarter, with approximately 61,500 clinical cases, up
21% year over year,” said David Dean Halbert, Founder, Chairman and CEO of Caris
Life Sciences. “Every case we run carries real molecular depth, whether Whole
Exome, Whole Transcriptome, Whole Genome, or AI-driven digital pathology, and
that depth is what allows us to move across the entire cancer journey. Caris
Assure® is now available for therapeutic response monitoring, and Caris Confirm,
our Whole Genome, tumor-informed assay for minimal residual disease, is targeted
to launch before year-end. It all comes back to making precision medicine a
reality for every patient through a comprehensive, data-driven approach.”
Recent Operating Highlights
• Launched Caris Assure Therapy Response Monitoring, extending the Caris Assure
blood-based platform from therapy selection to serial monitoring of treatment
response.
• Launched enhanced Caris Assure for Therapy selection with therapy focused
sequencing depth reaching 40,000x and increasing RNA reads to ~600M.
• Published validation of the Caris AI Insights™ pancreatic cancer signature,
demonstrating that an AI-based molecular signature can predict first-line
treatment benefits.
• Share repurchase program of up to $100.0 million, of which approximately $72.1
million remains available for repurchase under the existing Board authorization.
• Launched two national advertising campaigns featuring Kevin Costner and Jordan
Spieth, spotlighting the importance of early-stage cancer detection and
introducing Caris Detect™ to a consumer audience.
• Surpassed 1,200,000 total profiles and 845,000 total matched profiles through
September 30, 2026. More than 849,000 Whole Transcriptome and 796,000 Whole
Exome profiles through September 30, 2026.
Third Quarter 2026 Financial Results
Total revenue was $275.4 million for the three months ended September 30, 2026,
compared to $216.8 million for the three months ended September 30, 2025, an
increase of $58.5 million, or 27%.
The increase in total revenue was driven primarily by a 27% growth in molecular
profiling services revenue, which was $262.7 million for the three months ended
September 30, 2026, compared to $207.6 million for the three months ended
September 30, 2025. The increase in molecular profiling services revenue was
primarily driven by an increase in total clinical case volume and ASP
improvements.
Gross profit, calculated as total revenue less cost of services, for the three
months ended September 30, 2026 and 2025, was $182.3 million and $147.5 million,
respectively, representing a gross margin of 66% and 68%, respectively.
Operating expenses were $163.0 million for the three months ended September 30,
2026, compared to $114.9 million for the three months ended September 30, 2025,
an increase of $48.1 million, or 42%. The increase was primarily driven by
headcount-related costs, increased research and development investment, and
marketing expenditures.
Net income was $15.3 million for the three months ended September 30, 2026, as
compared to a net income of $24.3 million for the three months ended September
30, 2025. Net income per share attributable to common shareholders, basic and
diluted, was $0.05 and $0.05, respectively, for the three months ended September
30, 2026, as compared to a net income per share attributable to common
shareholders, basic and diluted, of $0.09 and $0.08, respectively, for the three
months ended September 30, 2025.
Net cash used in operating activities was $22.2 million for the three months
ended September 30, 2026, as compared to net cash provided by operating
activities of $62.4 million for the three months ended September 30, 2025, a
136% decrease. The decrease was driven by continued investment in commercial
expansion and marketing expenditures, inventory build-up for new solution
launches, and research and development efforts.
2026 Financial Outlook and Guidance
Caris Life Sciences now expects full year 2026 revenue to be in the range of
$1.04 to $1.05 billion, representing growth of 28% to 29% compared to full year
2025 and reaffirms its guidance for clinical therapy selection volume growth of
approximately 20% compared to full year 2025.
Conference Call Information
Event: Caris Third Quarter 2026 Financial Results Conference Call
Date: Wednesday, November 4, 2026
─────────────────────────────────────────────────────────────────────────────
Time: 3:30 p.m. CT (4:30 p.m. ET)
Webcast Link: https://edge.media-server.com/mmc/p/nri9afky
Accompanying materials will be posted on our investor relations website at
https://investor.carislifesciences.com prior to the conference call. A replay of
the conference call will be available on our investor relations website shortly
after the conclusion of the call.
About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading TechBio company actively developing
and commercializing innovative solutions to transform healthcare. Through
comprehensive molecular profiling (Whole
Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine
learning, Caris has created the large-scale, multimodal clinico-genomic database
and computing capability needed to analyze and further unravel the molecular
complexity of disease. This convergence of next-generation sequencing, AI and
machine learning technologies and high-performance computing provides a
differentiated platform for developing the latest generation of advanced
precision medicine diagnostic solutions for early detection, diagnosis,
monitoring, therapy selection and drug development.
Caris was founded with a vision to realize the potential of precision medicine
to improve the human condition. Headquartered in Irving, Texas, Caris has
offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan and Basel,
Switzerland. Caris or its distributor partners provide services in the U.S. and
other international markets.
We intend to use the investor page of our website,
https://investor.carislifesciences.com , as a distribution channel of material
information about the Company and for complying with our disclosure obligations
under Regulation FD. The information we post on our investor webpage may be
deemed material. Accordingly, investors should subscribe to our investor alerts,
in addition to following our press releases, SEC filings, public conference
calls and webcasts.
Forward-Looking Statements
This press release contains forward-looking statements, within the meaning of
the Private Securities Litigation Reform Act of 1995 and other federal
securities laws. All statements other than statements of historical facts
contained in this press release are forward-looking statements, including
statements regarding our business, solutions, plans, objectives, goals, industry
trends, financial outlook and guidance. In some cases forward-looking statements
can be identified by words such as “may,” “will,” “should,” “would,” “expect,”
“plan,” “anticipate,” “could,” “intend,” “target,” “project,” “potential,”
“contemplate,” “believe,” “estimate,” “predict,” or “continue” or similar
expressions.
You should not rely upon forward-looking statements as predictions of future
events. Although we believe that the expectations reflected in these forward-
looking statements are reasonable based on information currently available to
us, we cannot guarantee that the future results, discoveries, levels of
activity, performance or events and circumstances reflected in forward-looking
statements will be achieved or occur. Forward-looking statements involve known
and unknown risks and uncertainties, some of which are beyond our control. Risks
and uncertainties that could cause our actual results to differ materially from
those indicated or implied by the forward-looking statements in this press
release include, among other things: continued development, performance and
commercialization of Caris Detect and Caris Confirm; developments in the
precision medicine industry; our future financial performance, results of
operations or other operational results or metrics; development, analytical and
clinical validation, timing and performance of future solutions by us and our
competitors; commercial market acceptance for our solutions, including
acceptance of preventive as well as diagnostic testing paradigms, and our
ability to meet resulting demand; the rapidly evolving competitive environment
in which we operate; third-party payer reimbursement and coverage decisions
related to our solutions, including the effect of legislative, regulatory, or
administrative actions on reimbursement; the impact on our future volumes of the
continued execution of our strategy to re-align and expand our sales
organization; risks related to data management, storage, and processing
capabilities and our ability to integrate and deploy artificial intelligence and
advanced data analytics technologies; our ability to protect and enhance our
intellectual property; regulatory requirements, decisions or approvals
(including the timing and conditions thereof) related to our solutions; reliance
on third-party suppliers; risks related to data security, patient privacy, and
compliance with healthcare data protection regulations as well as potential
cybersecurity threats to our data platforms; our compliance with laws and
regulations; the outcome of government
investigations and litigation; risks related to our indebtedness; and our
ability to hire and retain key personnel as well as risks, uncertainties, and
other factors described in the section titled “Risk Factors” and elsewhere in
our Annual Report on Form 10-K filed on March 3, 2026, and in our other filings
we make with the SEC from time to time. We undertake no obligation to update any
forward-looking statements to reflect changes in events, circumstances or our
beliefs after the date of this press release, except as required by law.
Non-GAAP Measures
We use Adjusted EBITDA and free cash flow, financial measures not calculated in
accordance with generally accepted accounting principles in the United States
(“GAAP”), to supplement our condensed consolidated financial statements, which
are presented in accordance with GAAP. We believe the non-GAAP financial
measures we use, are useful in evaluating our performance and liquidity. Our
non-GAAP financial measures have limitations as analytical tools, however, and
you should not consider them in isolation or as substitutes for analysis of our
results as reported under GAAP. Other companies, including other companies in
our industry, may not use these measures or may calculate these measures
differently than as presented herein, limiting their usefulness as comparative
measures.
We define Adjusted EBITDA as net income (loss), adjusted to exclude interest
income, interest expense, changes in fair value of financial instruments, other
expense, net, the provision for (benefit from) income taxes, depreciation and
amortization, and stock-based compensation expense. We use Adjusted EBITDA in
conjunction with GAAP measures as part of our overall assessment of our
performance, including the preparation of our annual operating budget and
quarterly forecasts, to evaluate the effectiveness of our business strategies,
and to communicate with our board of directors concerning our financial
performance. We believe Adjusted EBITDA provides useful information to investors
and others in understanding and evaluating our operating results in the same
manner as our management team and board of directors. Adjusted EBITDA provides a
useful measure for period-to-period comparisons of our business, as it removes
the effect of certain non-cash expenses and certain variable charges. We define
free cash flow as net cash provided by (used in) operating activities less
capitalized software and purchases of property and equipment. Our method of
calculating free cash flow is unchanged from prior periods; the caption has been
updated to identify capitalized software as a component of our investing capital
expenditures. We believe free cash flow is a useful measure of liquidity that
provides an additional basis for assessing our ability to generate cash.
A reconciliation of the non-GAAP financial measures used in this press release
to the respective comparable GAAP financial measures, can be found below.
Caris Life Sciences Media:
Corporate Communications
[email protected]
214.294.5606
Investor Relations:
[email protected]
917.689.3511
CARIS LIFE SCIENCES, INC
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
(UNAUDITED)
(…
in
t…
e…
s… Thr… Nine
a… Mon… Mon…
p… End… End…
s… Sep… Sep…
d… 30, 30,
R… 2026 20… 2026 20…
──────────────────────────────────────────────────────────────────────────────
M…
p… $ 26… $ 207… $ 72… $ 484…
s…
P…
r…
a… 12… 9,2… 29… 34,…
d…
s…
T… 27… 216… 75… 519…
r…
C…
a…
o…
e…
C…
of
S…
- 89… 66,… 24… 193…
M…
p…
s…
C…
of
S…
-
P… 3,… 2,3… 8,… 7,6…
r…
a…
d…
s…
S…
a… 59… 41,… 15… 123…
m…
e…
G…
a… 69… 51,… 19… 168…
a…
e…
R…
a… 33… 21,… 97… 69,…
d…
e…
T…
c…
a… 25… 184… 70… 562…
o…
e…
I…
(… 19… 32,… 51… -43…
f…
o…
O…
e…
n…
I… 6,… 7,3… 19… 9,4…
i…
I… -9… -13… -3… -45…
e…
C…
in
f…
v… — -2,… — -52…
of
f…
i…
O…
i… 475 -89 -2… -18…
(…
n…
T…
o… -2… -8,… -3… -10…
e…
n…
I…
(…
b… 16… 24,… 15… -15…
i…
t…
I…
t… -1… — -1… —
e…
N…
i… 15… 24,… 14… -15…
(…
O…
c…
i…
(…
n…
of
t…
U…
l…
on -1… — -4… —
a…
s…
F…
c… -4… 79 -6… 538
t…
a…
C…
i… 14… 24,… 13… -14…
(…
N…
i…
(…
a…
to
c…
s…
N…
i… 15… 24,… 14… -15…
(…
D…
d…
f…
S…
D — — — -38…
r…
c…
p…
s…
A…
of
r…
c…
p… — — — -85…
s…
to
r…
v…
N…
i…
(…
a… $ 15… $ 24,… $ 14… $ -61…
to
c…
s…
N…
i…
(…
p…
s…
a…
to
c…
s…
B… $ 0.… $ 0.09 $ 0.… $ -4.…
D… $ 0.… $ 0.08 $ 0.… $ -4.…
W…
s…
u…
in
c…
n…
i…
(…
p…
s…
a…
to
c…
s…
B… 283… 28… 283… 12…
D… 295… 29… 294… 12…
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
(amounts in
thousands,
except share
data)
Assets As of September As of December
Current 30, 31,
assets: 2026 2025
──────────────────────────────────────────────────────────────────────────────
Cash, cash
equivalents, $ 665,321 $ 797,799
and restricted
cash
Short-term
marketable 102,059 2,295
securities
Accounts 133,322 112,140
receivable
Supplies 138,372 63,625
Prepaid
expenses and 28,194 21,941
other current
assets
Total current 1,067,268 997,800
assets
Property and 102,295 63,170
equipment, net
Goodwill 19,344 19,344
Other assets 66,716 45,349
Total assets $ 1,255,623 $ 1,125,663
Liabilities
and
Shareholders'
Equity
Current
liabilities:
Accounts $ 63,836 $ 39,206
payable
Accrued
expenses and 95,021 87,770
other current
liabilities
Current
portion of 89 169
indebtedness
Total current 158,946 127,145
liabilities
Long-term
indebtedness, 393,178 378,823
net
Other
long-term 64,018 42,388
liabilities
Total 616,142 548,356
liabilities
Commitments
and
contingencies
Shareholders'
equity:
Preferred
stock, $0.001
par value per
share;
100,000,000
shares
authorized as
of September
30, 2026 and
December 31, — —
2025; no
shares issued
and
outstanding
as of
September 30,
2026 and
December
31, 2025
Common stock,
$0.001 par
value per
share;
2,800,000,000
shares
authorized
as of
September 30,
2026 and
December
31, 2025;
286,717,657
and
284,137,810
shares issued
as of
September 30,
2026
and December
31, 2025,
respectively;
286,717,657
and 287 283
282,526,097
shares
outstanding as
of September
30, 2026 and
December 31,
2025,
respectively;
shares
issued and
outstanding
include 3,288
and
23,446
unvested
shares subject
to
repurchase as
of September
30, 2026 and
December 31,
2025,
respectively
Treasury stock
at cost, 0 and
1,611,713
shares of
common stock
as of — -16,896
September
30, 2026 and
December 31,
2025,
respectively
Additional
paid-in 3,173,932 3,141,720
capital
Accumulated -2,534,633 -2,548,736
deficit
Accumulated
other
comprehensive -105 936
income
(loss)
Total
shareholders' 639,481 577,307
equity
Total
liabilities
and $ 1,255,623 $ 1,125,663
shareholders'
equity
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
(amounts in thousands) Nine Months Ended
Cash flows from September 30,
operating activities 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net income (loss) $ 14,103 $ -150,045
Adjustments to
reconcile net income
(loss) to net cash
provided by operating
activities:
Depreciation and 18,209 18,324
amortization
Stock-based 56,589 56,639
compensation expense
Non-cash operating 4,321 4,323
lease expense
Amortization of debt 3,234 12,163
discounts
Changes in fair value
of financial — 52,284
instruments
Loss on debt 25,232 17,930
extinguishment
Other 3,074 788
Changes in operating
assets and
liabilities:
Accounts receivable -21,182 61,232
Supplies -78,467 -11,144
Prepaid expenses and
other current -5,711 -4,805
assets
Other assets -409 -326
Accounts payable 18,042 -1,196
Accrued expenses and 2,072 -17,792
other liabilities
Net cash provided by
operating 39,107 38,375
activities
Cash flows from
investing activities
Sale of marketable 1,874 —
securities
Purchases of -101,991 —
marketable securities
Capitalized software
and purchases of -49,887 -11,170
property and equipment
Net cash used in -150,004 -11,170
investing activities
Cash flows from
financing activities
Payments made on
finance lease -125 -67
obligations
Proceeds from exercise 26,054 3,775
of stock options
Payment of taxes
withheld from net
settlement of -5,426 -18,218
exercised options and
vested RSUs
Payment of deferred — -7,710
offering costs
Repurchase of common -31,371 -22
stock
Repayment of the 2023 -406,307 —
term loan
Proceeds from the 2026
term loan, net of 393,500 —
issuance costs
Payment of third-party
debt issuance -1,107 —
costs
Proceeds from share
purchases under 2,937 —
employee stock
purchase plan
Issuance of Series E
Preferred Stock, — 87,637
net of issuance costs
Issuance of Series F
Preferred Stock, — 33,601
net of issuance costs
Issuance of the 2025
Convertible Notes, — 27,865
net of issuance costs
Issuance of the 2025 — 10,270
Warrants
Payments of the 2023
term loan amendment — -4,000
fee
Proceeds from initial
public offering,
net of underwriting — 528,459
discounts and
commissions
Net cash provided by
(used in) financing -21,845 661,590
activities
Effect of exchange
rate changes on cash, -149 159
cash equivalents, and
restricted cash
Net increase
(decrease) in cash,
cash -132,891 688,954
equivalents, and
restricted cash
Cash, cash
equivalents, and
restricted 800,042 68,028
cash at beginning of
period
Cash, cash
equivalents, and $ 667,151 $ 756,982
restricted
cash at end of period
Reconciliation of
cash, cash
equivalents, and
restricted cash
Cash, cash
equivalents, and $ 665,321 $ 754,739
restricted
cash
Restricted cash
included in other 1,830 2,243
long-term assets
Total cash, cash
equivalents, and $ 667,151 $ 756,982
restricted cash
RECONCILIATION OF GAAP NET INCOME (LOSS) TO ADJUSTED EBITDA (UNAUDITED)
Three Nine
Months Months
(amou… Ended Ended
in Septe… Septe…
thous… 2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Net
inco… $ 15,250 $ 24,325 $ 14,103 $ -150,0…
(los…
Inte… -6,332 -7,360 -19,9… -9,482
inco…
Inte… 9,249 13,507 31,286 45,497
expe…
Chan…
in
fair
value — 2,081 — 52,285
of
fina…
inst…
Other
inco… -475 89 24,607 18,447
(exp…
net
Inco…
tax 1,624 — 1,513 —
expe…
Depr…
and 6,606 4,870 18,209 18,324
amor…
expe…
Stoc…
comp… 18,498 13,655 56,589 56,639
expe…
Adju… $ 44,420 $ 51,167 $ 126,3… $ 31,665
EBIT…
RECONCILIATION OF NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES TO FREE
CASH FLOW (UNAUDITED)
Three Nine
Months Months
(amou… Ended Ended
in Septe… Septem…
thous… 2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Net
cash
prov…
by $ -22,2… $ 62,425 $ 39,107 $ 38,375
(used
in)
oper…
acti…
Less:
capi…
soft…
and
purc… -17,4… -7,095 -49,887 -11,1…
of
prop…
and
equi…
Free
cash $ -39,7… $ 55,330 $ -10,780 $ 27,205
flow